



Download

Share

Export

COVID-19 campus closures: [see options for getting or retaining Remote Access to subscribed content](#)

## Microbiological Research

Volume 168, Issue 5, 12 June 2013, Pages 254-262

# *In vitro* antimicrobial and anticancer potential of hinokitiol against oral pathogens and oral cancer cell lines

Yin-Hua Shih <sup>a</sup>, Kuo-Wei Chang <sup>a, b</sup>, Shih-Min Hsia <sup>c</sup>, Cheng-Chia Yu <sup>d</sup>, Lih-Jyh Fuh <sup>e</sup>, Tzu-Yun Chi <sup>f</sup>, Tzong-Ming Shieh <sup>f, g</sup>  

 **Show more**

<https://doi.org/10.1016/j.micres.2012.12.007>

[Get rights and content](#)

Under an Elsevier [user license](#)

[open archive](#)

## Abstract

Hinokitiol is a natural component isolated from *Chamacyparis taiwanensis*. It has [anti-microbial activity](#), and has been used in oral care products. The [minimal inhibitory concentration](#) (MIC) and minimal microbicidal concentration (MBC) of hinokitiol against MRSA, *Aggregatibacter actinomycetemcomitans*, *Streptococcus mutans*, and *Candida albicans* were determined by the agar and [broth dilution](#) methods. The paradoxical inhibition phenomenon (PIP) was observed in *A. actinomycetemcomitans* and *S. mutans*. The PIP can be described as [microbial growth](#) at high and low concentrations of a compound, between which no growth was observed. The PIP was confirmed using a kinetic microplate and [inhibition zone](#) methods. The PIP was also observed in MRSA. The low [autolysin](#) activity somehow correlated to the PIP positive. The cell diameter was increased in all the pathogens, and the transition was inhibited in *C. albicans* following hinokitiol treatment. Hinokitiol is also a potential anticancer drug. The 200  $\mu$ M of hinokitiol has significant antimicrobial and cytotoxic activities against oral pathogens and oral squamous cell carcinoma cell lines, respectively, and lower cytotoxic effects for normal human oral [keratinocytes](#), indicating that hinokitiol displays a high potential for safe and effective applications in oral health care.

## Start tracking your Reading History

Sign in and never lose track of an article again.

[Register for free >](#)



Download

Share

Export

## Keywords

Autolysin; Hinokitiol; Minimal inhibitory concentrations; Minimal microbicidal concentration; Oral squamous cell carcinoma; Paradoxical inhibition phenomenon (PIP)

## 1. Introduction

The timber of the Taiwan cypress tree *Chamacyparis taiwanensis* is resistant to insects, fungi, and bacteria, making it one of the most resilient building materials used since ancient times. Hinokitiol is a chemical compound of aromatic [tropolone](#) and a component of essential oils first isolated from the heart wood of *C. taiwanensis*. Early clinical uses included treatments for lung gangrene, tuberculous fistula, pulmonary tuberculosis, and decubitus ulcers.

Hinokitiol shows antibacterial, antifungal, antiviral, and insecticidal activities ([Inamori et al., 2000](#), [Arima et al., 2003](#), [Krenn et al., 2009](#)). Certain health care products contain hinokitiol, such as safe preservatives for toothpaste, cosmetics, hair tonics, oral care gel, eyelid cleanser, hair restorers, skin lotions, and body soap, because of its multi-biological activities ([Higashi et al., 2009](#), [Gilbard et al., 2010](#), [Nagao and Sata, 2011](#)). However, few studies have been conducted on hinokitiol antimicrobial mechanisms. *Staphylococcus aureus* that was isolated from [atopic dermatitis](#) patients was inhibited by 50 µg/mL hinokitiol ([Arima et al. 2003](#)). Exposure to 500 µg/mL hinokitiol for 30 min did not cause morphological changes in *Escherichia coli* IFO 3301 and *S. aureus* IFO 12732 cells; however, [cellular respiration](#), [nucleic acid synthesis](#), and [protein synthesis](#) were reduced ([Morita et al.](#)). *Candida albicans* strains was 5–10 µg/mL, hinc expression but did not inhibit ATP synthesis also been shown to inhibit influenza virus replication *mansoni* ([Miyamoto et al., 1998](#), [Chisty et al., 2012](#)).

The oral cavity is a warm, humid, and hypoxic environment where oral pathogens flourish. Caries, periodontal disease, and candidiasis are common oral diseases that often result from imbalances between the normal [oral microflora](#) and host immunity. *MRSA* is a facultative-anaerobic *Staphylococcus* sp. for which the colonization and infection is 77.8% among oral cancer patients following surgery ([Miyake et al. 2007](#)). *Aggregatibacter actinomycetemcomitans* is a spherical or rod-shaped bacterium that colonizes the periodontal pockets of oral cavities and damages tooth-supporting tissues. *Streptococcus mutans* is a facultative-anaerobic *Streptococcus* sp. that is common in the human oral cavity and significantly contributes to dental caries. The fungal pathogen *C. albicans* causes oral candidiasis in immune deficient humans, such as cancer, transplants, and AIDS patients.

### Start tracking your Reading History

Sign in and never lose track of an article again.

[Register for free >](#)



Download

Share

Export

Hinokitiol has also been shown to cause [apoptosis](#) and [cell cycle arrest](#) in murine embryonal [carcinoma cells](#) (Tanaka et al. 1999). Treatments with 5 µg/mL hinokitiol for 24 and 48 h produced cytotoxic effects in a murine P388 lymphocytic [leukemia cell line](#), and 50 µM hinokitiol blocked [androgen receptor signal transduction](#), inhibiting the growth of the [prostate cancer cell line LNCaP](#) (Liu and Yamauchi 2006). Hinokitiol was also shown to induce caspase-3-mediated apoptosis through a time- and dosage-dependent suppression of [DNA synthesis](#) in murine F9 teratocarcinoma cells (Ido et al. 1999). However, no [developmental toxicity](#) or carcinogenic effects have been observed for hinokitiol (Ema et al., 2004, Imai et al., 2006). Thus, Hinokitiol has demonstrated specific antimicrobial and anticancer properties. The purpose of our study was to examine the antimicrobial and cytotoxic properties of hinokitiol for clinical applications for oral disease pathogens and oral [squamous cell carcinoma](#) (OSCC). We examined the antimicrobial and cytotoxic properties of hinokitiol on oral disease pathogens and OSCC. We verified hinokitiol MIC and MMC in MRSA, *A. actinomycetemcomitans*, *S. mutans*, and *C. albicans*, and found hinokitiol the PIP in MRSA, *A. actinomycetemcomitans*, and *S. mutans*. The hinokitiol PIP is associated with bacterial [autolysin](#) activity. The microbes in the study were swollen, and *C. albicans* transition was inhibited after hinokitiol treatment. Hinokitiol has significant [antimicrobial and cytotoxic activities](#) against oral pathogens and OSCC cell lines, respectively, and lower cytotoxic effects for normal human oral [keratinocytes](#) (OK).

## 2. Materials and methods

### 2.1. Microorganisms culture

Methicillin-resistant *S. aureus* (MRSA, ATCC number: 33591), *A. actinomycetemcomitans* (ATCC number: 33384), *S. mutans* (ATCC number: 25791), and *C. albicans* (ATCC number: 90020) were used in this study. The [MRSA](#) and *S. mutans* were cultured in [Methicillin-resistant Staphylococcus aureus](#) (MRSA) broth, *A. actinomycetemcomitans* was cultured in brain heart infusion (BHI) broth, and *C. albicans* was cultured in a [yeast extract peptone](#) dextrose medium. Bacteria were transferred from frozen tube slants of 3 mL to 10 mL of the appropriate medium and incubated overnight. Selected colonies were transferred to the appropriate liquid medium, and incubated 4–6 h to achieve log phase growth. The [optical density](#) at 600 nm (OD<sub>600</sub>) of each culture was adjusted to 1.0 using fresh broth to give a standard [inoculum](#) of 10<sup>6</sup> cfu/mL, which was verified by counting colony numbers on agar media following a 10-fold series dilution. Stock cultures were maintained at –80 °C in growth broth containing 15% sterile glycerol.

### 2.2. Minimum inhibition concentration and minimum microbicidal concentration determinations Agar dilution method

Start tracking your Reading History

Sign in and never lose track of an article again.

Register for free >



Download

Share

Export

broth, and CHX was prepared in DMSO. Nutrient agar medium (0.2%) containing concentrations of hinokitiol between 5  $\mu$ M and 200  $\mu$ M, and 0.2% DMSO (0  $\mu$ M hinokitiol, control) were prepared in a 12-well plate format (2 mL/well). Chlorhexidine (CHX, Sigma–Aldrich), a popular antimicrobial agent in mouthwashes, was used as a parallel control in our study. Bacterial cultures were prepared on a solid medium using 2  $\mu$ L of  $10^6$  cfu/mL, and were incubated in the dark at 37 °C overnight (*C. albicans*, yeast form in 30 °C, and hyphal form in 37 °C). The solid medium containing the least concentration of hinokitiol and CHX, which showed no visible growth, represented the MIC. MIC is the lowest concentration of an antimicrobial that inhibits the visible growth of a microorganism after overnight incubation. The MIC plates were swabbed with a sterile inoculating loop that was then used to inoculate a 6 cm nutrient broth agar plate, which was hinokitiol free, and the 6 cm plates were then incubated for 24 h. The left and right side of the agar plate were used for the agar dilution method MMC and broth dilution method MMC, respectively. The least concentration at which no growth was observed represented the MMC. MMC is the lowest concentration of antibiotic required to kill a particular microorganism.

### 2.3. Broth dilution method

The broth dilution method was modified from Mohapatra's methods (Mohapatra et al. 2011). Cell suspensions were prepared in 2 mL of liquid medium with various hinokitiol and CHX concentrations in 15 mL culture tubes by inoculation with 2  $\mu$ L of  $10^6$  cfu/mL from each glycerol stock. The cultures were incubated at 30 or 37 °C at 250 rpm for 24 h, and OD600 for 10-fold dilutions of each culture. Tubes showing no visible turbidity represented the MIC, and subsequently, were inoculated on the right side of the sterile 6 cm nutrient agar plates without hinokitiol and incubated for 24 h. The least concentration, at which no growth was observed, represented the MMC.

### 2.4. Kinetic microplate method

The kinetic microplate test was conducted in previously described method (Holowachuk et al. 2011). Concentrations of hinokitiol in 1 mL of liquid medium were inoculated with 1  $\mu$ L of  $10^6$  cfu/mL from the glycerol stock. The cultures were incubated in 96-well plates. Unused wells were filled with 200  $\mu$ L of water to prevent evaporation.

The 24-h kinetic analysis of the culture growth was performed at the species-appropriate incubation temperature (30 or 37 °C). The kinetic analysis included a 5-s shaking step before each of the time point measurements of OD600 that were recorded at 30 min intervals and analyzed using VersaMax™ and Softmax® Pro (version 5.4.1) software, respectively.

### 2.5. Inhibition zone

#### Start tracking your Reading History

Sign in and never lose track of an article again.

Register for free >





Download

Share

Export

equilibrated in a 50 °C water bath for 30 min following autoclave sterilization. Cultures were inoculated with 10<sup>6</sup> cfu/mL of glycerol stock by swirling before being poured into plates. The dried filters placed on the surface of the solidified agar, and the cultures were incubated for 24 h at 30 or 37 °C. The diameter of the [inhibition zone](#) was recorded and photographed.

## 2.6. *C. albicans* transitional assay

*C. albicans* were treated with 0.2% DMSO, 25, 50, 100, and 200 µM hinokitiol in colony morphological tests, hyphal morphological tests, and germ tube formation ability tests.

### I. Colony morphological test

*C. albicans* were cultured on YPD agar containing 4% FBS, 80 mg/mL [uridine](#), and different dosages of hinokitiol in 37 °C for 3 d.

### II. Hyphal morphological test

*C. albicans* were cultured on bacto agar containing 4% FCS, 80 mg/L uridine, 20 mg/L [arginine](#), 20 mg/L [histidine](#), and different dosages of hinokitiol in 37 °C for 7 d.

### III. Germ tube formation ability test

*C. albicans* were cultured in YPD agar with different dosages of hinokitiol in 30 °C for 1 d, and then inoculated in YPD broth contained 80 mg/L uridine, and incubated in 37 °C for 3 h. The germ tubes were observed and photographed by [light microscopy](#).

## 2.7. Scanning electron microscope

The test microorganisms were treated with 200 µM hinokitiol. and adsorbed on a glass slide. The cells were fixed using 4% glutaraldehyde ethanol washes, and dried with tertiary-butyl palladium, and the colonies were observed us [electron microscope](#) (SEM).

## 2.8. Autolysin activity

Determinations of the ability of MRSA, *A. actinomycetemcomitans*, and *S. mutans* to produce [autolysin](#) were performed using a modified solid medium assay ([Fontana et al. 1990](#)). Autolysin activity was defined as the ability to lyse heat-killed bacteria. MRSA, *A. actinomycetemcomitans*, and *S. mutans* were heat-killed by autoclaving and used as substrates. The heat-killed bacteria were added to molten BHI or TSB agar, and OD600 was adjusted to 0.5. Following solidification, 10 µL of the test pathogen were spotted onto the agar surface, and the plates were incubated at 30 or 37 °C for 24–48 h. Bacteria that showed a clear lysis zone on heat-killed bacteria plates were deemed autolysin producers.

**Start tracking your Reading History**

Sign in and never lose track of an article again.

[Register for free >](#)



Download

Share

Export

University Hospital). The OSCC cell lines HSC3, SAS, and SCC4 were kindly gifted by Dr. M.-C. Kao (China Medical University). These cell lines were cultured, and [cell viability](#) after 24 h hinokitiol treatment was used for the MTT test as described ([Shieh et al., 2010](#), [Shih et al., 2012](#)).

## 2.10. Statistical analysis

All the assays were duplicate to quadruplicate. The Mann–Whitney test was used for analysis. Data were shown as the mean  $\pm$  standard error. Differences between the variants were considered significant when  $p < 0.05$ .

## 3. Results


### 3.1. MIC and MMC of hinokitiol determined by agar/broth dilution methods

The [agar dilution](#) method was used to determine hinokitiol [MIC](#) of [MRSA](#), *A. actinomycetemcomitans*, *S. mutans*, and *C. albicans*. The hinokitiol MIC values for *MRSA*, *A. actinomycetemcomitans*, *S. mutans*, *C. albicans* yeast form, and hyphal form were 110, 90, 70, 60, and 90  $\mu\text{M}$ , respectively. However, the [antibacterial activity](#) of hinokitiol exhibited a paradoxical inhibition phenomenon (PIP) for *A. actinomycetemcomitans*, and *S. mutans* bacteria. The PIP can be described as [microbial growth](#) occurring in the presence of both high and low concentrations of an antimicrobial compound, between which microbial growth is inhibited. No *A. actinomycetemcomitans* growth was observed in the presence of 10–30  $\mu\text{M}$  hinokitiol, but growth was observed in the presence of 40–80  $\mu\text{M}$  hinokitiol. Similarly, no *S. mutans* growth was observed in the presence of 10–40  $\mu\text{M}$  hinokitiol, but growth was observed in the presence of 50–70  $\mu\text{M}$  hinokitiol. In a parallel control experiment, the CHX MIC for *MRSA*, *A. actinomycetemcomitans*, *S. mutans*, and *C. albicans* respectively. No PIP effect was observed with ([Fig. 1A](#)).

Start tracking your Reading History

Sign in and never lose track of an article again.

Register for free >



[Download : Download full-size image](#)

Fig. 1. Agar/broth dilution methods determination of the hinokitiol MIC/MMC for MRSA, *A. actinomycetemcomitans* (Aa), *S. mutans* (Sm), and *C. albicans* (Ca). Hinokitiol, from 0 to 200  $\mu\text{M}$ , and CHX, from 0 to 8  $\mu\text{g/mL}$ . (A) Agar dilution method, MIC. (B) Broth dilution method, MIC. (C) Agar/broth dilution methods MMC. The agar dilution method is represented on the left side of the plate, and the broth dilution method on the right. NC indicates the negative control (no microorganism).

The broth dilution method was used to verify the MIC of hinokitiol for MRSA, *A. actinomycetemcomitans*, *S. mutans*, *C. albicans* yeast form, and hyphal form cells were 100, 70, 70, 40, and 80  $\mu\text{M}$ , respectively. The PIP was also observed for *A. actinomycetemcomitans*, and *S. mutans*. The *A. actinomycetemcomitans* culture medium was clear for the 5–20  $\mu\text{M}$  hinokitiol samples, but the culture was turbid in the 30–60  $\mu\text{M}$ . The *S. mutans* culture medium was clear for the 10–40  $\mu\text{M}$  hinokitiol samples, but the culture was turbid in the 50–60  $\mu\text{M}$ . Using the broth dilution method, the CHX MIC for MRSA, *A. actinomycetemcomitans*, *S. mutans*, and *C. albicans* yeast form were <1, <1, <1, and 4  $\mu\text{g/mL}$ , respectively (Fig. 1B).

Start tracking your Reading History

Sign in and never lose track of an article again.

Register for free >



Download

Share

Export

are represented on the right side. The MMC values for hinokitiol of MRSA, *A.*

*actinomycetemcomitans*, *S. mutans*, *C. albicans*, yeast form, and hyphal form, which were determined using the agar dilution method, were 130, 90, 80, 60, and 130  $\mu\text{M}$ . However, *A.*

*actinomycetemcomitans* and *S. mutans* growth were not observed in 10  $\mu\text{M}$ , or 10–30  $\mu\text{M}$  hinokitiol samples, respectively. The MMC values for hinokitiol of MRSA, *A.*

*actinomycetemcomitans*, *S. mutans*, *C. albicans*, yeast form, and hyphal form that were determined using the broth dilution method were 130, 70, 80, 50, and 90  $\mu\text{M}$ . *A. actinomycetemcomitans* and

*S. mutans* growth were not observed in the 10  $\mu\text{M}$ , and 10–40  $\mu\text{M}$  hinokitiol samples, respectively. The CHX MMC that was determined using the broth dilution method was 2, <1,

<1, and 4  $\mu\text{g/mL}$  for MRSA, *A. actinomycetemcomitans*, *S. mutans*, and *C. albicans*, respectively (Fig. 1C).

### 3.2. The MRSA PIP of hinokitiol was detected by the kinetic growth curve and inhibition zone test

In the kinetic analysis, the value under the curve was the highest detected value of OD600 during 24 h in each sample. The result of kinetic analysis showed that the MIC and PIP were consistent in the broth dilution method in *A. actinomycetemcomitans*, and *C. albicans*, but different in MRSA and *S. mutans*. *S. mutans* growth was inhibited in the presence of 10–60  $\mu\text{M}$  hinokitiol, significant growth occurred in the presence of 70–130  $\mu\text{M}$  hinokitiol, and growth was again inhibited in the presence of 140  $\mu\text{M}$  hinokitiol (Fig. 2A). An OD600 greater than 0.02 was defined as the starting point of the log phase of microbial growth. The OD600 was 0.685 for the 20  $\mu\text{M}$  hinokitiol samples but was 1.131 for the 30  $\mu\text{M}$  hinokitiol samples in MRSA, indicating that growth was more extensive at a higher hinokitiol concentration. The inhibition of microbial growth in the 0 and 80  $\mu\text{M}$  hinokitiol samples is shown in Fig. 2B. The MRSA, *A. actinomycetemcomitans*, *S. mutans*, and *C. albicans* log phases were 4, 6.5, 6, and 8 h in duration, respectively. Although the PIP of MRSA was 11 h, it was 11 h for *A. actinomycetemcomitans*, 11 h for *S. mutans*, and 11 h for *C. albicans*.


dilution methods based on growth at 24 h, it was 11 h for *A. actinomycetemcomitans* (Fig. 2B). Plotting the area under the growth curve (AUC) using the linear curve that was used to quantify the antimicrobial activity (Fig. 2B). The results of agar/broth dilution and kinetic analysis are shown in Table 1. Antimicrobials are usually regarded as bactericidal if the MIC is less than 100  $\mu\text{g/mL}$ . The data indicated that hinokitiol is an

Start tracking your Reading History

Sign in and never lose track of an article again.

Register for free >





Download : Download full-size image

Fig. 2. MIC, MMC, and PIP of hinokitiol determined by kinetic microplate and inhibition zone method. (A) Growth curve analysis of MRSA, A. actinomycetemcomitans, S. mutans, and C. albicans in the presence of hinokitiol (0–200 μM) using the kinetic microplate method. The value above the curve represents hinokitiol concentration, and the value below the curve represents the maximum OD600 during the 24 h period. (B) Growth in the presence of hinokitiol, 0–80 μM. (C) Plots of area under the growth curve (AUGC) versus hinokitiol concentration yielded diagram of curves. (D) Hinokitiol inhibition zone tests. Drops of DMSO containing 50.0, 25.0, 12.5, 6.25, 3.13, 1.56, 0.781–0.325 μg hinokitiol were absorbed on the filter paper discs labeled 1–8, respectively. Discs D and E contained 6 μL DMSO and no reagent. (E) The diameter of inhibition zone plotted for each microorganism. The dotted line represents the diameter of the disc (6 mm). (F) C. albicans transitional test in panel is colony, the middle panel is filament,

Start tracking your Reading History

Sign in and never lose track of an article again.

Register for free >

Table 1. Hinokitiol and CHX MIC/MMC.

Hinokitiol (μM)	CHX (μg/mL)
-----------------	-------------



	(MIC/MMC)	(MIC/MMC)	method (MIC)		(MIC/MMC)
	Agar dilution method (MIC/MMC)	Broth dilution method (MIC/MMC)	Kinetic microplate method (MIC)	Agar dilution method (MIC)	Broth dilution method (MIC/MMC)
MRSA	110/130	100/130	160	5	<1/2
Aa	90/90	70/70	70	4	<1/<1
	PIP: 10–30/10	PIP:5–20/10	PIP: 5–20		
Sm	80/80	70/80	140	5	<1/<1
	PIP: 10–40/10–30	PIP: 10–40/10–40	PIP: 10–60		
Ca (yeast)	60/60	40/50	50	5	4/4
Ca (hyphal)	90/130	80/90	–	–	–

MIC, MMC, and PIP data for hinokitiol and CHX treatments of [MRSA](#), *A. actinomycetemcomitans* (Aa), *S. mutans* (Sm), and *C. albicans* (Ca) in 3 independent experiments using the [agar dilution](#) method, the [broth dilution](#) method, and the kinetic microplate method.

The PIP of hinokitiol that was observed for *A. actinomycetemcomitans* and *S. mutans* bacteria was also demonstrated in the results of the [inhibition zone](#) test. In the analysis of MRSA, the inhibition zone of the 50 µg hinokitiol disc was larger than that of the 25 µg disc with light growth that was visible in the outermost area indistinct for the 12.5 µg disc, and no clearly hinokitiol disc for the MRSA. The 25 and 50 µg discs showed a distinct area of *A. actinomycetemcomitans*, and *S. mutans* proximal to the disc and a distal region in which the inhibition zone was dose-dependent for the 0.38–1.5 µg hinokitiol discs regarding *A. actinomycetemcomitans*, and *S. mutans* growth ([Fig. 2D](#)). The diameters of the inhibition zones are shown in [Fig. 2E](#). There were no significant differences between the data collected at 24 and 48 h. In the *C. albicans* transitional test, wrinkled colonies were observed in the control, and smooth colonies were observed in 25, 50, and 100 µM hinokitiol. The colony numbers, size, filaments density, and germ-tube lengths were decreased by hinokitiol in a dose dependent manner. No visible colony, filament, or germ tube was observed in 200 µM of hinokitiol. The data demonstrated that hinokitiol could block the yeast-to-hyphal transition and germ tube formation in *C. albicans* ([Fig. 2F](#)).



Download

Share

Export


25, 50, 100, and 200  $\mu\text{M}$  hinokitiol for 24 h (Fig. 3A). SEM analysis showed that morphological changes occurred in MRSA, *A. actinomycetemcomitans*, *S. mutans*, and *C. albicans* cells following treatment with 200  $\mu\text{M}$  hinokitiol for 24 h, with all species exhibiting increases in cell diameter. In addition, the SEM images show that *C. albicans* wrinkled and ruptured following hinokitiol treatment (Fig. 3B). The changes in cell diameter that were measured for MRSA, *A. actinomycetemcomitans*, *S. mutans*, and *C. albicans* before and after hinokitiol treatment were  $0.64 \pm 0.024$  to  $0.86 \pm 0.040$   $\mu\text{m}$ ,  $p = 0.011$ ;  $1.00 \pm 0.084$   $\mu\text{m}$  to  $1.60 \pm 0.114$ ,  $p = 0.016$ ;  $0.79 \pm 0.010$  to  $1.00 \pm 0.032$   $\mu\text{m}$ ,  $p = 0.0097$ ; and  $3.04 \pm 0.160$  to  $3.78 \pm 0.017$   $\mu\text{m}$ ,  $p = 0.0358$ , respectively (Fig. 3C). The pH of the culture media did not significantly decrease following the addition of 200  $\mu\text{M}$  hinokitiol. The pH of the TSB medium (MRSA and *S. mutans*) before and after addition of hinokitiol was 7.42–7.41, respectively. The pH of the BHI medium (Aa) was 7.06–7.05, respectively, and the pH of the YPD medium (Ca) was 6.21–6.19, respectively.

### Start tracking your Reading History



Sign in and never lose track of an article again.

Register for free >



Download : Download full-size image

Fig. 3. Morphological examination using scanning electron microscopy. (A) The morphology of untreated cells is represented in the left panel, and cell morphology following treatment with 200 μM hinokitiol is shown in the right panel. The photographs of MRSA, A. actinomycetemcomitans, and S. mutans were taken at 20,000× magnification, and those of C. albicans were taken at 4000× magnification. (B) The diameter of the cells treated with and without the 200 μM hinokitiol treatment was analyzed using the Mann–Whitney test. The asterisk indicates  $p < 0.05$ , and the double asterisk indicates  $p < 0.01$ .




Download

Share

Export

of agar plates tested (heat-killed MRSA in TSB agar, heat-killed *A. actinomycetemcomitans* in BHI agar, and heat-killed *S. mutans* in TSB agar). The MRSA bacteria displayed high autolysin activity in all three agar types. We considered that the high autolysin activity observed for the MRSA bacteria may have been the result of higher cell density, compared with that of the *A. actinomycetemcomitans*, and *S. mutans*, cells, because the MRSA replication rate was relatively higher. However, [inoculation](#) with one-eighth and one-half the volume of the original MRSA inoculum did not decrease the autolysin radius (data not showed). There were no significant differences observed between the data collected at 24 and 48 h ([Fig. 4](#)).




[Download](#) : [Download full-size image](#)

Fig. 4. [Autolysin](#) activity tests of [MRSA](#), *A. actinomycetemcomitans*, and *S. mutans*. The panels represent results on day 1 (left) and day 2 (right). Heat-killed MRSA, *A. actinomycetemcomitans*, and *S. mutans* cells were used as the substrates. The MRSA was inoculated on the lower-right

### 3.5. OSCC were more sensitive to hinokitiol than OK

The results of the [MTT assay](#) analysis of [cell viability](#) for the OSCC cell lines HSC3, SAS, and SCC4 showed that treatment with 200  $\mu\text{M}$  hinokitiol resulted in growth rates of 15%, 45%, and 30%, respectively. However, the OK cell viability was 65% following hinokitiol treatment, indicating that the effect of hinokitiol was significantly greater in the cancer cells. In addition, although the CHX control treatment displayed a greater cytotoxic in OK cells than in the OSCC cell lines ([Fig. 5A and B](#)).



[Download : Download full-size image](#)

Fig. 5. Cytotoxicity for hinokitiol and CHX treatments of OK and OSCC cell lines, HSC3, SAS, and SCC4. (A) hinokitiol, MTT test, (B) CHX, MTT test.

## 4. Discussion

The [MIC](#) and MMC of hinokitiol obtained for different methods that were used for the evaluation of the result of different incubation conditions, liquid culturing methods, culture volume, the methods, and aeration. For example, the [broth](#) 15 mL tube but the kinetic growth curve analysis recording in 96-well plates. Shaking of culture increases dissolved oxygen and increases the growth of aerobic [microorganisms](#). However, although facultative [anaerobes](#) grow well under such conditions, growth rates may be suboptimal, compared with anaerobic conditions.

Numerous antibiotics were recommended at [higher dosages](#) for patients with serious infections. That can cause a theoretical risk if the antibiotic is PIP positive. We investigated hinokitiol MIC, MMC, and PIP dosage in oral pathogens for this reason. All 3 methods demonstrated a significant PIP for both *A. actinomycetemcomitans* and *S. mutans* and the MIC and MMC values were similar for each. However, although [MRSA](#) did not exhibit the PIP in

**Start tracking your Reading History**

Sign in and never lose track of an article again.

[Register for free >](#)





Download

Share

Export

growth reached the stationary phase ( $OD_{600} = 0.002$ ), which may explain why the PIP was not observed using the agar/broth dilution methods. The values of the CHX MIC and MMC for MRSA, *A. actinomycetemcomitans*, *S. mutans*, and *C. albicans* were similar to those reported in previous studies (Holbrook and Kippax, 1979, Meurman et al., 1989, Sheng et al., 2009), which validates our results.

The PIP has been reported for penicillin, caspofungin, and hinokitiol; however, the mechanism of the PIP for these antimicrobials is unknown (Eagle, 1948, Arima et al., 2003, Stevens et al., 2004). One explanation is that a high-concentration antimicrobial agent might be self-antagonising the receptor, such as penicillin. An antimicrobial agent could possibly precipitate out of the solution so that the antibacterial activity is either not seen or the colorimeter is detecting crystals of the antimicrobial. The possibility of hinokitiol precipitates has been excluded because the  $OD_{600}$  of BHI containing 5–200  $\mu$ M hinokitiol without *A. actinomycetemcomitans* did not significantly increase ( $OD_{600} = 0.000$ – $0.002$ ) and no precipitates were observed after centrifuging at 3000 rpm for 5 min in our study (data not showed). The PIP was obvious in the gram-positive (MRSA and *S. mutans*) and gram-negative bacteria (*A. actinomycetemcomitans*). This suggests that the PIP of hinokitiol was not associated with gram-stain classification.

Autolysins are naturally produced by peptidoglycan-containing bacteria. Peptidoglycan hydrolytic autolysins are critical for separating daughter cells after cell division (Zoll et al. 2010). Excessive autolysin degrades the peptidoglycan matrix and causes the cell to burst because of osmotic pressure (Blackman et al. 1998). Fine-tuned spatial and temporal control of autolysins could maintain the peptidoglycan network and prevent suicidal cell death (Rice and Bayles 2003). Autolytic defects often lead to antibiotic tolerance (Mitchell and Tuomanen 2002). *Enterococcus faecalis* treated with penicillin displayed the PIP, and the PIP was associated with autolysin activity (Fontana et al. 1990). The autolysin activity observed in our study was highest for MRSA and lowest for *A. actinomycetemcomitans*. The relationship between autolysin activity and the PIP was similar to that of the previous penicillin study (Fontana et al. 1990).

Hinokitiol reduced *E. coli* IFO 3301 and *S. aureus* growth, and inhibited autolysin synthesis, and protein synthesis (Morita et al. 2003).

*C. albicans* IFO 1 (CYR1), and RAS1, which function in the regulation of hyphal growth. *efg1* and *cph1* were regulated by RAS signal transmission, and they might be inhibited by hinokitiol to block *C. albicans* hyphal growth transition (Brown and Gow 1999). However, whether hinokitiol treatment blocks *C. albicans* hyphal from formation because of *efg1* and *cph1* gene down-regulation requires further investigation in the future.

The PIP of hinokitiol might have implications for long-term antimicrobial treatments for oral disease prevention because high doses of hinokitiol are progressively diluted by saliva over time, resulting in a subsequent, second antimicrobial treatment at the lower concentration of

**Start tracking your Reading History**

Sign in and never lose track of an article again.

Register for free >



Download

Share

Export

CHX is commonly used in mouthwash to reduce dental plaque and oral bacteria, but it is harmful at high concentrations. In our [cytotoxicity tests](#), the OK cells were more sensitive to CHX than the OSCC cell lines. However, the OK cells were less sensitive to hinokitiol, compared with the significant reductions in the viability in all the OSCC cell lines that were observed following hinokitiol treatment, according to the results of the [MTT assays](#). This suggests a high degree of safety for potential uses of hinokitiol for oral disease prevention and therapy. In addition, as an anticancer agent that demonstrates specific inhibition of cancer cell growth and low cytotoxicity in normal cells, the combination of the anti-cancer and the anti-bacterial properties of hinokitiol indicate that it may be useful for the treatment of oral cancer patients following surgery. Hinokitiol has been used in oral health care products, such as toothpaste, mouth wash, and oral care gel; however, hinokitiol must still be analyzed carefully in greater detail before clinical application in oral disease prevention and therapy.

## Acknowledgments

This study was supported by a grant from China Medical University ([CMU98-OC-05](#)) and a grant from the National Science Council, Taiwan ([NSC 99-2314-B-039-023-MY3](#)). We wish to thank Dr. C.-H. Lai, and Dr. H.-T. Chang of China Medical University for kindly providing the [MRSA](#), and [C. albicans](#). We thank Dr. S.-L. Huang of Yang-Ming University for the kindly providing the *A. actinomycetemcomitans*, and *S. mutans*. We also wish to acknowledge the efforts of Instrumentation Resource Center of the UST-YMU, especially Dr. T.-S. Yeh for his valuable technical support.

[Recommended articles](#)
[Citing articles \(38\)](#)

## References

[Arima et al., 2003](#) Y. Arima, Y. Nakai, R. Haya  
**Antibacterial effect of beta-thujaplicin  
 dermatitis: relationship between change  
 clinical improvement in an eczematous**  
 J Antimicrob Chemother, 51 (1) (2003),  
[View Record in Scopus](#) [Google Scholar](#)

[Blackman et al., 1998](#) S.A. Blackman, T.J. Smith, S.J. Foster  
**The role of autolysins during vegetative growth of *Bacillus subtilis* 168**  
 Microbiology, 144 (Pt 1) (1998), pp. 73-82  
[CrossRef](#) [View Record in Scopus](#) [Google Scholar](#)

[Brown and Gow, 1999](#) A.J. Brown, N.A. Gow  
**Regulatory networks controlling *Candida albicans* morphogenesis**  
 Trends Microbiol, 7 (8) (1999), pp. 333-338

## Start tracking your Reading History



Sign in and never lose track of an article again.

[Register for free >](#)

[Download](#)[Share](#)[Export](#)

**Transmission electron microscopy of *Schistosoma mansoni* cercariae treated with hinokitiol (beta-thujaplicin), a compound for potential skin application against cercarial penetration**

Tohoku J Exp Med, 202 (1) (2004), pp. 63-67

[CrossRef](#) [Google Scholar](#)

[Eagle, 1948](#) H. Eagle

**A paradoxical zone phenomenon in the bactericidal action of penicillin in vitro**

Science, 107 (2767) (1948), pp. 44-45

[View Record in Scopus](#) [Google Scholar](#)

[Ema et al., 2004](#) M. Ema, A. Harazono, S. Fujii, K. Kawashima

**Evaluation of developmental toxicity of beta-thujaplicin (hinokitiol) following oral administration during organogenesis in rats**

Food Chem Toxicol, 42 (3) (2004), pp. 465-470

[Article](#)  [Download PDF](#) [View Record in Scopus](#) [Google Scholar](#)

[Fontana et al., 1990](#) R. Fontana, M. Boaretti, A. Grossato, E.A. Tonin, M.M. Lleo, G. Satta

**Paradoxical response of *Enterococcus faecalis* to the bactericidal activity of penicillin is associated with reduced activity of one autolysin**

Antimicrob Agents Chemother, 34 (2) (1990), pp. 314-320

[CrossRef](#) [View Record in Scopus](#) [Google Scholar](#)

[Gilbard et al., 2010](#) J.P. Gilbard, Y. Douyon, R.B. Huson

**Time-kill assay results for a linalool-hinokitiol-based eyelid cleanser for lid hygiene**

Cornea, 29 (5) (2010), pp. 559-563

[View Record in Scopus](#) [Google Scholar](#)

[Higashi et al., 2009](#) Y. Higashi, M. Sakata, Y. I

**High-performance liquid chromatography for measurement of hinokitiol in pers**

J Cosmet Sci, 60 (5) (2009), pp. 519-525

[View Record in Scopus](#) [Google Scholar](#)

[Holbrook and Kippax, 1979](#) W.P. Holbrook, R. Kippax

**Sensitivity of *Candida albicans* from patients with chronic oral candidiasis**

Postgrad Med J, 55 (647) (1979), pp. 692-694

[CrossRef](#) [View Record in Scopus](#) [Google Scholar](#)

[Holowachuk et al., 2003](#) S.A. Holowachuk, M.F. Bal'a, R.K. Buddington

**A kinetic microplate method for quantifying the antibacterial properties of biological fluids**

J Microbiol Methods, 55 (2) (2003), pp. 441-446

**Start tracking your Reading History**

Sign in and never lose track of an article again.

[Register for free >](#)



Download

Share

Export

**Induction of apoptosis by hinokitiol, a potent iron chelator, in teratocarcinoma F9 cells is mediated through the activation of caspase-3**

Cell Prolif, 32 (1) (1999), pp. 63-73

[View Record in Scopus](#) [Google Scholar](#)

[Imai et al., 2006](#) N. Imai, Y. Doi, K. Nabae, S. Tamano, A. Hagiwara, M. Kawabe, *et al.*

**Lack of hinokitiol (beta-thujaplicin) carcinogenicity in F344/DuCrj rats**

J Toxicol Sci, 31 (4) (2006), pp. 357-370

[CrossRef](#) [View Record in Scopus](#) [Google Scholar](#)

[Inamori et al., 2000](#) Y. Inamori, Y. Sakagami, Y. Morita, M. Shibata, M. Sugiura, Y. Kumeda, *et al.*

**Antifungal activity of Hinokitiol-related compounds on wood-rotting fungi and their insecticidal activities**

Biol Pharm Bull, 23 (8) (2000), pp. 995-997

[CrossRef](#) [View Record in Scopus](#) [Google Scholar](#)

[Komaki et al., 2008](#) N. Komaki, T. Watanabe, A. Ogasawara, N. Sato, T. Mikami, T. Matsumoto

**Antifungal mechanism of hinokitiol against *Candida albicans***

Biol Pharm Bull, 31 (4) (2008), pp. 735-737

[CrossRef](#) [View Record in Scopus](#) [Google Scholar](#)

[Krenn et al., 2009](#) B.M. Krenn, E. Gaudernak, B. Holzer, K. Lanke, F.J. Van Kuppeveld, J. Seipelt

**Antiviral activity of the zinc ionophores pyrithione and hinokitiol against picornavirus infections**

J Virol, 83 (1) (2009), pp. 58-64

[CrossRef](#) [View Record in Scopus](#) [Google Scholar](#)

[Liu and Yamauchi, 2006](#) S. Liu, H. Yamauchi

**Hinokitiol, a metal chelator derived from hinokiol, disrupts androgen receptor signaling in prostate cancer cells**

Biochem Biophys Res Commun, 351 (1) (2006), pp. 1-5

[Article](#) [Download PDF](#) [View Record in Scopus](#) [Google Scholar](#)

[Meurman et al., 1989](#) J.H. Meurman, H. Jousimies-Somer, P. Suomala, S. Alaluusua, H. Torkko, S. Asikainen

**Activity of amine-stannous fluoride combination and chlorhexidine against some aerobic and anaerobic oral bacteria**

Oral Microbiol Immunol, 4 (2) (1989), pp. 117-119

[View Record in Scopus](#) [Google Scholar](#)

[Mitchell and Tuomanen, 2002](#) L.S. Mitchell, E.I. Tuomanen

**Start tracking your Reading History**

Sign in and never lose track of an article again.

[Register for free >](#)



Download

Share

Export

[Article](#) [Download PDF](#) [CrossRef](#) [View Record in Scopus](#) [Google Scholar](#)[Miyake et al., 2007](#) M. Miyake, Y. Ohbayashi, A. Iwasaki, T. Ogawa, S. Nagahata**Risk factors for methicillin-resistant *Staphylococcus aureus* (MRSA) and use of a nasal mupirocin ointment in oral cancer inpatients**

Int J Oral Maxillofac Surg: Off J Am Assoc Oral Maxillofac Surg, 65 (11) (2007), pp. 2159-2163

[Article](#) [Download PDF](#) [View Record in Scopus](#) [Google Scholar](#)[Miyamoto et al., 1998](#) D. Miyamoto, Y. Kusagaya, N. Endo, A. Sometani, S. Takeo, T. Suzuki, *et al.***Thujaplicin-copper chelates inhibit replication of human influenza viruses**

Antiviral Res, 39 (2) (1998), pp. 89-100

[Article](#) [Download PDF](#) [View Record in Scopus](#) [Google Scholar](#)[Mohapatra et al., 2011](#) D.P. Mohapatra, V. Thakur, S.K. Brar**Antibacterial efficacy of raw and processed honey**

Biotechnol Res Int, 2011 (2011), p. 917505

[Google Scholar](#)[Morita et al., 2007](#) Y. Morita, Y. Sakagami, T. Okabe, T. Ohe, Y. Inamori, N. Ishida**The mechanism of the bactericidal activity of hinokitiol**

Biocontrol Sci, 12 (3) (2007), pp. 101-110

[CrossRef](#) [View Record in Scopus](#) [Google Scholar](#)[Nagao and Sata, 2011](#) Y. Nagao, M. Sata**Effect of oral care gel on the quality of life for oral lichen planus in patients with chronic HCV infection**

Virol J, 8 (2011), p. 348

[CrossRef](#) [Google Scholar](#)[Rice and Bayles, 2003](#) K.C. Rice, K.W. Bayles**Death's toolbox: examining the molecular death**

Mol Microbiol, 50 (3) (2003), pp. 729-736

[View Record in Scopus](#) [Google Scholar](#)[Sheng et al., 2009](#) W.H. Sheng, J.T. Wang, T.L. Lauderdale, C.M. Weng, D. Chen, S.C. Chang**Epidemiology and susceptibilities of methicillin-resistant *Staphylococcus aureus* in Taiwan: emphasis on chlorhexidine susceptibility**

Diagn Microbiol Infect Dis, 63 (3) (2009), pp. 309-313

[Article](#) [Download PDF](#) [View Record in Scopus](#) [Google Scholar](#)[Shieh et al., 2010](#) T.M. Shieh, K.W. Chang, H.F. Tu, Y.H. Shih, S.Y. Ko, Y.C. Chen, *et al.***Start tracking your Reading History**

Sign in and never lose track of an article again.

[Register for free >](#)





Download

Share

Export

Shih et al., 2012 (2012), pp. 3407-3411

[Article](#)[Download PDF](#)[View Record in Scopus](#)[Google Scholar](#)[Shih et al., 2012](#) Y.H. Shih, K.W. Chang, M.Y. Chen, C.C. Yu, D.J. Lin, S.M. Hsia, *et al.***Lysyl oxidase and enhancement of cell proliferation and angiogenesis in oral squamous cell carcinoma**Head Neck (2012), [10.1002/hed.22959](#)

[Epub ahead of print]

[Google Scholar](#)[Stevens et al., 2004](#) D.A. Stevens, M. Espiritu, R. Parmar**Paradoxical effect of caspofungin: reduced activity against *Candida albicans* at high drug concentrations**

Antimicrob Agents Chemother, 48 (9) (2004), pp. 3407-3411

[View Record in Scopus](#) [Google Scholar](#)[Tanaka et al., 1999](#) T. Tanaka, T. Satoh, Y. Onozawa, J. Kohroki, N. Itoh, M. Ishidate Jr., *et al.***Apoptosis during iron chelator-induced differentiation in F9 embryonal carcinoma cells**

Cell Biol Int, 23 (8) (1999), pp. 541-550

[Article](#)[Download PDF](#)[CrossRef](#)[View Record in Scopus](#)[Google Scholar](#)[Young, 2006](#) K. Young**In vitro antibacterial resistance selection and quantitation**

Curr Protoc Pharmacol (2006)

Chapter 13: Unit 13A 6

[Google Scholar](#)[Zoll et al., 2010](#) S. Zoll, B. Patzold, M. Schlag,**Structural basis of cell wall cleavage by**

PLoS Pathogens, 6 (3) (2010), p. e10008

[CrossRef](#)[Google Scholar](#)**Start tracking your Reading History**

Sign in and never lose track of an article again.

[Register for free >](#)

Copyright © 2012 Elsevier GmbH. All rights reserved.

[About ScienceDirect](#)[Remote access](#)[Shopping cart](#)

[Download](#)[Share](#)[Export](#)[Terms and conditions](#)[Privacy policy](#)

We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the **use of cookies**.

Copyright © 2020 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.

ScienceDirect® is a registered trademark of Elsevier B.V.



## Start tracking your Reading History



Sign in and never lose track of an article again.

[Register for free >](#)